TocosolPaclitaxel posts

Feed

Flash: Sonus (SNUS) gets murdered - plummeting over 80%

Sonus Pharmaceuticals (NASDAQ:SNUS) logoIn news that shows how dangerous investing in small-cap biotechs can be, Sonus Pharmaceuticals (NASDAQ: SNUS) said that its late-stage trials of breast cancer drug Tocosol Paclitaxel have failed.

Sonus shares are down 85%, and are the most actively traded on any US exchange. The stock changes hands at $0.70 down from a 52-week high of $6.32.

Sonus has been something of a one-trick pony. Its revenue has been in the $3 million to $5 million range over each of the last four quarters when it lost $25 million.

With $42 million in cash on the balance sheet, at least the company has some time.

Douglas A. McIntyre is a partner at 24/7 Wall St.

Symbol Lookup
IndexesChangePrice
DJIA-74.9212,454.83
NASDAQ-1.852,837.53
S&P 500-2.861,317.82

Last updated: May 27, 2012: 10:08 PM

Hot Stocks

General Electric

19.20-0.05(-0.26)

Alcoa

8.630.00(0.00)

Apple Inc

562.29-3.03(-0.54)

Google Inc 'A'

591.53-12.13(-2.01)

Bank of America

7.15+0.01(+0.14)

Wal-Mart Stores

65.31+0.24(+0.37)

Exxon Mobil Corp

82.08-0.53(-0.64)

Ford

10.60+0.01(+0.09)

Citigroup

26.47-0.19(-0.71)

IBM

194.30-1.79(-0.91)

Yahoo

15.36+0.01(+0.07)

Starbucks

54.56-0.20(-0.37)

Microsoft

29.06-0.01(-0.03)

Home Depot

49.44-0.27(-0.54)

DailyFinance Headlines

AOL Business News

BioHealth Investor Headlines

Sponsored Links

My Portfolios

Track your stocks here!

Find out why more people track their portfolios on AOL Money & Finance then anywhere else.

BloggingStocks Partners

More from AOL Money & Finance

Page Loaded in 1338170902731 ms.